Trial Profile
A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- 20 Apr 2016 Status changed from active, no longer recruiting to completed.
- 31 Mar 2015 Results published in the peer-reviewed journal Cancer Medicine, according to Peregrine Pharmaceuticals media release.
- 31 Mar 2015 Results published in the Media Release.